Article date: July 2019
By: Oliver Pohl, Line Marchand, Jean‐Pierre Gotteland, Simon Coates, Jörg Täubel, Ulrike Lorch in Volume 85, Issue 7, pages 1516-1527
Aims
To investigate presence or absence of clinically relevant drug interactions (pharmacokinetic and safety/tolerability) of OBE022 with standard‐of‐care medicines for preterm labour, enabling coadministration and further clinical development.
Methods
Part A: open‐label, randomized, 3‐period crossover assessing coadministration of single doses of OBE022 (1100 mg) and MgSO4. Part B: open‐label, single‐sequence crossover assessing the interactions following administration of OBE022 (1000 mg/day) at steady state coadministered with single doses of atosiban, nifedipine and betamethasone. Twenty‐five healthy nonpregnant women of reproductive age were enrolled (Part A: n = 12; Part B: n = 13).
Results
OBE022, alone or in combination with standard‐of‐care medications, was well tolerated. Headache and dizziness were the most frequently reported adverse events; dizziness occurred more often with the nifedipine/OBE022 combination. There were no clinically significant pharmacokinetic interactions when coadministered with MgSO4. Co‐administration had no notable effect on atosiban exposure. Atosiban reduced exposure to OBE002 (peak concentration [Cmax] 22%, area under the concentration–time curve [AUC] 19%). Coadministration with betamethasone slightly increased betamethasone exposure (Cmax + 18%, AUC +27%) and OBE002 exposure (Cmax + 35%, AUC +15%). These changes were not considered clinically significant. Coadministration with nifedipine slightly increased OBE002 exposure (Cmax + 29%, AUC +24%) and markedly increased nifedipine exposure (Cmax by 2‐fold and AUC by 2‐fold), which may be clinically significant.
Conclusions
The use of OBE022, a PGF2α antagonist prodrug, in combination with standard‐of‐care medicines may provide new treatment alternatives for preterm labour. All tested combinations were well tolerated. Nifedipine doses could potentially be reduced or staggered when coadministered with OBE022.
DOI: 10.1111/bcp.13925
View this article